Capital Asset Advisory Services LLC Sells 5,853 Shares of Abbott Laboratories $ABT

Capital Asset Advisory Services LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 13.2% in the first quarter, Holdings Channel reports. The fund owned 38,485 shares of the healthcare product maker’s stock after selling 5,853 shares during the period. Capital Asset Advisory Services LLC’s holdings in Abbott Laboratories were worth $3,695,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ABT. J. Stern & Co. LLP increased its position in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new position in Abbott Laboratories in the fourth quarter valued at about $2,938,892,000. Invesco Ltd. grew its stake in Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Abbott Laboratories by 303.0% during the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares in the last quarter. Finally, Ninety One UK Ltd bought a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $336,815,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott Laboratories with an Outperform rating and a $121 price target, signaling strong upside potential and renewed Wall Street confidence. Article Title
• Positive Sentiment: Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which could expand Abbott’s CGM ecosystem and support diabetes-care sales. Article Title
• Positive Sentiment: Wells Fargo reiterated a Buy rating on Abbott Laboratories, adding to the positive analyst sentiment around the stock. Article Title
• Positive Sentiment: TipRanks highlighted Abbott as one of the dividend aristocrats that Wall Street currently likes, reinforcing the view that it remains a favored defensive healthcare name. Article Title
• Neutral Sentiment: Recent coverage compared Abbott with Intuitive Surgical, but the article was more of a broader healthcare-stock debate than a direct catalyst for Abbott’s shares. Article Title
• Neutral Sentiment: Abbott-related commentary on multi-cancer blood screening and broader healthcare trends is informative for the sector, but it does not appear to be a direct company-specific catalyst. Article Title
• Negative Sentiment: Abbott also faced headlines about a closed U.S. criminal probe into its infant-formula plant and a proposed civil settlement, which could remain a legal overhang even if the worst-case risk has eased. Article Title

Abbott Laboratories Stock Performance

ABT stock opened at $92.15 on Thursday. The company has a 50 day moving average price of $88.83 and a 200 day moving average price of $104.62. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market capitalization of $160.51 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 1.56 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings lowered Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Evercore reduced their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Jefferies Financial Group decreased their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus lowered their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $118.42.

Insider Activity

In other news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.